141 related articles for article (PubMed ID: 36241697)
61. A meta-analysis on Rituximab combined CHOP chemotherapy for non-Hodgkin lymphoma in China.
Hou S; Yang W
Saudi Med J; 2011 Jul; 32(7):675-8. PubMed ID: 21748202
[TBL] [Abstract][Full Text] [Related]
62. Prognostic value of complete remission status at end-of-treatment FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: systematic review and meta-analysis.
Adams HJ; Nievelstein RA; Kwee TC
Br J Haematol; 2015 Jul; 170(2):185-91. PubMed ID: 25833790
[TBL] [Abstract][Full Text] [Related]
63. Limited role of interim PET/CT in patients with diffuse large B-cell lymphoma treated with R-CHOP.
Yoo C; Lee DH; Kim JE; Jo J; Yoon DH; Sohn BS; Kim SW; Lee JS; Suh C
Ann Hematol; 2011 Jul; 90(7):797-802. PubMed ID: 21181163
[TBL] [Abstract][Full Text] [Related]
64. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
[TBL] [Abstract][Full Text] [Related]
65. Interim PET response criteria in paediatric non-Hodgkin's lymphoma. Results from a retrospective multicenter reading.
Furth C; Erdrich AS; Steffen IG; Ruf J; Stiebler M; Kahraman D; Kobe C; Schönberger S; Grandt R; Hundsdoerfer P; Hauptmann K; Amthauer H; Hautzel H
Nuklearmedizin; 2013; 52(4):148-56. PubMed ID: 23928982
[TBL] [Abstract][Full Text] [Related]
66. FDG-PET/CT after two cycles of R-CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome - final result of a UK National Cancer Research Institute prospective study.
Mikhaeel NG; Cunningham D; Counsell N; McMillan A; Radford JA; Ardeshna KM; Lawrie A; Smith P; Clifton-Hadley L; O'Doherty MJ; Barrington SF
Br J Haematol; 2021 Feb; 192(3):504-513. PubMed ID: 32621535
[TBL] [Abstract][Full Text] [Related]
67. Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas.
Hagemeister F; Rodriguez MA; Deitcher SR; Younes A; Fayad L; Goy A; Dang NH; Forman A; McLaughlin P; Medeiros LJ; Pro B; Romaguera J; Samaniego F; Silverman JA; Sarris A; Cabanillas F
Br J Haematol; 2013 Sep; 162(5):631-8. PubMed ID: 23802738
[TBL] [Abstract][Full Text] [Related]
68. Liposomal doxorubicin supercharge-containing front-line treatment in patients with advanced-stage diffuse large B-cell lymphoma or classical Hodgkin lymphoma: Preliminary results of a single-centre phase II study.
Picardi M; Giordano C; Pugliese N; Esposito M; Fatigati M; Muriano F; Rascato MG; Della Pepa R; D'Ambrosio A; Vigliar E; Troncone G; Russo D; Mascolo M; Esposito G; Prastaro M; Esposito R; Tocchetti CG; Fonti R; Mainolfi C; Del Vecchio S; Pane F
Br J Haematol; 2022 Sep; 198(5):847-860. PubMed ID: 35819919
[TBL] [Abstract][Full Text] [Related]
69. Prognostic significance of bone marrow 2-[
Lim CH; Hyun SH; Cho YS; Choi JY; Lee KH
Clin Radiol; 2021 Jul; 76(7):550.e19-550.e28. PubMed ID: 33762136
[TBL] [Abstract][Full Text] [Related]
70. Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma.
Burke JM; van der Jagt RH; Kahl BS; Wood P; Hawkins TE; MacDonald D; Hertzberg M; Simpson D; Craig M; Kolibaba K; Issa S; Munteanu M; Victor TW; Flinn IW
Clin Lymphoma Myeloma Leuk; 2016 Apr; 16(4):182-190.e1. PubMed ID: 26875824
[TBL] [Abstract][Full Text] [Related]
71. Is True Whole-Body
Cerci JJ; Etchebehere EC; Nadel H; Brink A; Bal CS; Rangarajan V; Pfluger T; Kagna O; Alonso O; Begum FK; Mir KB; Magboo VP; Menezes LJ; Paez D; Pascual TN
J Nucl Med; 2019 Aug; 60(8):1087-1093. PubMed ID: 30683766
[TBL] [Abstract][Full Text] [Related]
72. The frequency of change in five-point scale score with a Bayesian penalised likelihood PET reconstruction algorithm on interim FDG PET-CT and its potential implications for therapy decisions in Hodgkin's lymphoma.
Subesinghe M; Ilyas H; Dunn JT; Mir N; Duran A; Mikhaeel NG; Barrington SF
Clin Radiol; 2023 Feb; 78(2):e89-e98. PubMed ID: 36333130
[TBL] [Abstract][Full Text] [Related]
73.
Cottereau AS; Nioche C; Dirand AS; Clerc J; Morschhauser F; Casasnovas O; Meignan M; Buvat I
J Nucl Med; 2020 Jan; 61(1):40-45. PubMed ID: 31201248
[TBL] [Abstract][Full Text] [Related]
74. Utility of interim and end-of-treatment [(18)F]-fluorodeoxyglucose positron emission tomography-computed tomography in frontline therapy of patients with diffuse large B-cell lymphoma.
Huntington SF; Nasta SD; Schuster SJ; Doshi JA; Svoboda J
Leuk Lymphoma; 2015; 56(9):2579-84. PubMed ID: 25629993
[TBL] [Abstract][Full Text] [Related]
75. 18F-fluorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphoma.
Casulo C; Schöder H; Feeney J; Lim R; Maragulia J; Zelenetz AD; Horwitz S
Leuk Lymphoma; 2013 Oct; 54(10):2163-7. PubMed ID: 23369041
[TBL] [Abstract][Full Text] [Related]
76. Complete response in a frail patient with high-grade B-cell lymphoma to only one cycle of R-CHOP or to prolonged COVID-19?
Yilmaz F; Yasar S; Tuncali MC; Akin S
Semin Oncol; 2021; 48(4-6):279-282. PubMed ID: 34895738
[TBL] [Abstract][Full Text] [Related]
77. Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma.
Luminari S; Ferrari A; Manni M; Dondi A; Chiarenza A; Merli F; Rusconi C; Tarantino V; Tucci A; Vitolo U; Kovalchuk S; Angelucci E; Pulsoni A; Arcaini L; Angrilli F; Gaidano G; Stelitano C; Bertoldero G; Cascavilla N; Salvi F; Ferreri AJM; Vallisa D; Marcheselli L; Federico M
J Clin Oncol; 2018 Mar; 36(7):689-696. PubMed ID: 29095677
[TBL] [Abstract][Full Text] [Related]
78. Importance of Central Imaging Review in a Pediatric Hodgkin Lymphoma Trial Using Positron Emission Tomography Response Adapted Radiation Therapy.
Hoppe BS; McCarten KM; Pei Q; Kessel S; Alazraki A; Mhlanga JC; Lai HA; Eutsler E; Hodgson DC; Roberts KB; Charpentier AM; Keller FG; Voss SD; Wu Y; Cho SY; Kelly KM; Castellino SM
Int J Radiat Oncol Biol Phys; 2023 Aug; 116(5):1025-1030. PubMed ID: 36868525
[TBL] [Abstract][Full Text] [Related]
79. Paediatric and adolescent Hodgkin lymphoma: information derived from diffuse organ uptake of 18 F-fluorodeoxyglucose on pre-treatment and on interim PET/CT.
Jorgov L; Montravers F; Balogova S; Ragu C; Pacquement H; Leblanc T; Abbou S; Ducou-Lepointe H; Landman-Parker J; Talbot JN
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1220-30. PubMed ID: 26660144
[TBL] [Abstract][Full Text] [Related]
80. Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjögren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas.
Voulgarelis M; Giannouli S; Anagnostou D; Tzioufas AG
Rheumatology (Oxford); 2004 Aug; 43(8):1050-3. PubMed ID: 15187246
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
